US Material Events SEC 8-K Filings — July 02, 2026

02-07-2026

Beeline Holdings, Inc. acquired the remaining 52.4% of MagicBlocks, Inc. through a Securities Exchange Agreement effective June 30, 2026, making MagicBlocks a wholly-owned subsidiary. The transaction involved nominal cash consideration for selling shareholders, issuance of 211,679 shares to Third-Party SAFE Holders (including CEO Nicholas R. Liuzza, Jr., who received 31,111 shares at $2.25 per share), and cancellation of all outstanding MagicBlocks stock options. Separately, from May 27 to June 26, 2026, the company raised $1,575,098.23 in gross proceeds by selling 1,370,131 shares under an existing ELOC Agreement.

• · The transaction was negotiated and approved by a Special Committee of the Board comprised solely of disinterested directors due to CEO involvement.
• · CEO received 31,111 shares at $2.25 per share, which was materially above market.
• · All outstanding MagicBlocks stock options were cancelled as part of the agreement.
• · The ELOC share sales were made under an exemption from registration under Section 4(a)(2) of the Securities Act and Rule 506(b).

02-07-2026

Sintx Technologies entered into a Letter Agreement with MedTech Ceramics, LP on June 29, 2026, to resolve 507,254 shares held in abeyance from a September 2025 warrant inducement transaction. The agreement releases 255,267 shares for no additional consideration, replaces 251,987 shares with a pre-funded warrant, and cancels an existing 760,881-share warrant in exchange for a new warrant to purchase 1,268,135 shares at $2.14 per share. While the transaction aims to improve the company's stockholders' equity position, the outcome remains uncertain and dependent on overall financial performance.

• · The Pre-Funded Warrant has no fixed expiration date and is exercisable via a cashless mechanism with a 9.99% beneficial ownership limitation.
• · The New Warrant expires five years from issuance and includes a full-ratchet downward adjustment provision in any dilutive equity financing, subject to stockholder approval per Nasdaq Listing Rule 5635(d).
• · The company must file a resale registration statement covering shares issuable upon exercise of the New Warrant within 45 days.
• · The issuances are intended to be exempt from registration under Section 4(a)(2) and/or Regulation D of the Securities Act of 1933.

02-07-2026

Bluerock Private Real Estate Fund entered into an Administrative Services Agreement with its adviser, Bluerock Fund Advisor, LLC, effective July 1, 2026, to provide expanded administrative services as the fund rotates from institutional funds into direct real estate investments. The ASA fee is 0.20% of average managed assets, but the adviser voluntarily waived approximately 53% of the fee on assets still in institutional funds, resulting in significant net savings for shareholders. The fund also disclosed it has closed approximately $250 million in direct real estate investments and has an additional $450 million under contract or in its pipeline.

• · The ASA fee is calculated and paid monthly based on average daily managed assets (net assets plus borrowings plus preferred stock liquidation preference).
• · The ASA can be terminated by a majority of independent trustees, a majority of outstanding voting securities, or by the adviser upon 60 days' written notice without penalty.
• · The ASA covers services including NYSE listing compliance, secondary market support, proxy and annual meeting process, and Exchange Act reporting.
• · The adviser's liability is limited to cases of willful misfeasance, bad faith, gross negligence, or reckless disregard of obligations.

02-07-2026

American Rebel Holdings Inc. issued a $152,950 promissory note to 1800 Diagonal Lending LLC on June 23, 2026, receiving net proceeds of $133,000 after an original issue discount of $19,950. The note carries a 15% interest rate (18.75% one-time charge) and requires 15 monthly payments totaling $181,628, with a maturity date of September 30, 2027. However, the company faces a high effective cost of capital (implied interest of ~36.6% on net proceeds) and the note includes severe default penalties (150%-200% of outstanding) and cross-default provisions, indicating significant financial strain.

• · The note is secured by a Securities Purchase Agreement and includes cross-default provisions with all other debt of the borrower to the holder.
• · The company has a 5-day grace period for each monthly payment; a missed payment constitutes an Event of Default.
• · Upon an Event of Default, the holder can demand 150% of the outstanding principal plus accrued interest and default interest; this increases to 200% if a conversion default occurs.
• · The borrower cannot prepay except during the first 180 days, and then only at 95% of the outstanding amount (a 5% discount).
• · The note includes covenants restricting sale of significant assets without holder consent and requires the borrower to remain current with its transfer agent obligations.
• · The holder has conversion rights into common stock upon an Event of Default (other than conversion failure) and if the borrower fails to pay the Default Amount within 5 business days.

02-07-2026

Functional Brands Inc. amended CEO Eric Gripentrog's employment agreement on June 30, 2026, replacing a $500,000 RSU award with an option to purchase 3,500,000 shares at $0.0055 per share, fully vested immediately. The option has a grant-date fair value of approximately $14,685 and a total exercise price of $19,250. No negative or flat metrics are present.

• · The option is designated as an incentive stock option under Section 422 of the Internal Revenue Code.
• · Exercise price of $0.0055 per share equals the closing price on June 29, 2026.
• · Option expires on June 29, 2036, subject to earlier termination.
• · Upon cessation of service (other than death/disability), vested shares may be exercised within 3 months.

02-07-2026

Mobility Global Inc. completed its separation from S&P Global Inc., distributing 100% of shares to S&P Global stockholders on a one-for-one basis effective July 1, 2026, and began trading on the NYSE under the ticker 'MBGL'. Leadership, including CEO Bill Eager, CFO Matt Calderone, and Chairman Joe Hinrichs, highlighted the company's financial strength, trusted brands (CARFAX, automotiveMastermind, Polk Automotive Solutions, Market Scan), and century-long credibility. Risks remain high as the company now operates as an independent public company with no historical standalone performance, significant debt obligations, and exposure to cybersecurity, litigation, and macroeconomic volatility—all detailed in the forward-looking statement risk factors.

• · The distribution was based on a record date of June 15, 2026, with each S&P Global stockholder receiving one share of Mobility Global common stock per share held.
• · Fractional shares were not distributed; they will be sold in the open market and stockholders will receive a cash payment.
• · Mobility Global will incur significant costs to create the infrastructure necessary as an independent public company and may experience operational disruptions.
• · The company will have debt obligations that could restrict business flexibility and increase cost of debt funding.
• · The separation may not qualify as tax-free for U.S. federal income tax purposes, potentially leading to significant tax liabilities for S&P Global and/or its stockholders.
• · The company has no history of operating as an independent company, and its historical financial information is not necessarily representative of future results.
• · Risk factors include potential loss of key customer groups, failure to develop new products, cybersecurity threats, and intellectual property challenges.
• · A large number of shares may be eligible for future sale, which could depress the market price, and the stock may not be included in major indices like the S&P 500.

02-07-2026

S&P Global Inc. completed the separation of its Mobility division into an independent public company, Mobility Global Inc. (NYSE: MBGL), effective July 1, 2026. Stockholders received one share of Mobility Global for each S&P Global share held on the record date of June 15, 2026, with fractional shares sold for cash. The company expects to release recast financials on July 6, 2026, reflecting the spin-off, but no financial performance data for the current or prior period is provided in this filing.

• · The separation was completed on July 1, 2026, after 15 months of preparation.
• · Mobility Global common stock began regular-way trading on NYSE under ticker 'MBGL' on July 1, 2026.
• · Distribution of 100% of Mobility Global shares was made to S&P Global stockholders as of 12:01 a.m. New York City time on July 1, 2026.
• · Record date for the distribution was June 15, 2026.
• · Fractional shares were not distributed; instead, they will be sold in the open market with cash proceeds paid to stockholders.
• · S&P Global expects to issue a press release on July 6, 2026, providing recast financial information for full year 2025, the four quarters of 2025, and Q1 2026.
• · Financial advisors: Morgan Stanley, Goldman Sachs, Citigroup, Evercore. Legal advisors: Davis Polk & Wardwell and Baker McKenzie.

02-07-2026

EquipmentShare.com Inc closed a private offering of $1,350 million aggregate principal amount of 7.125% Senior Secured Second Lien Notes due 2034, issued at par. The notes mature on July 1, 2034, with interest payable semi-annually. The company has the option to redeem up to 10% of the notes at 103% of par within any twelve-month period before July 1, 2029, and up to 40% with equity offering proceeds at 107.125% of par. The notes are secured on a second-priority basis and rank pari passu with existing second lien notes, but are junior to the asset-based revolving credit facility.

• · The notes are not guaranteed by any subsidiary as of the issue date but will be guaranteed by future domestic subsidiaries that guarantee first-priority lien obligations.
• · The notes rank pari passu with existing 9.000% Senior Secured Second Lien Notes due 2028, 8.625% Senior Secured Second Lien Notes due 2032, and 8.000% Senior Secured Second Lien Notes due 2033.
• · The indenture includes customary high yield covenants limiting additional debt, dividends, liens, affiliate transactions, mergers, asset sales, and subsidiary dividend restrictions.
• · Interest on the notes is payable on January 1 and July 1, beginning January 1, 2027.

02-07-2026

Neurogene Inc. raised approximately $134.8 million in net proceeds through an underwritten public offering of 3,500,000 shares of common stock at $30.00 per share and pre-funded warrants for 666,666 shares at $29.999999 per warrant, with the underwriters fully exercising a 30-day option to purchase an additional 624,999 shares. The company expects the funds, combined with existing cash, to support operations into the first quarter of 2029. The offering closed on July 2, 2026, and the securities were offered under an effective shelf registration statement.

• · The underwriters fully exercised their 30-day option to purchase an additional 624,999 shares on July 1, 2026.
• · Pre-funded warrants are exercisable at any time after issuance, with a beneficial ownership cap of 4.99% or 9.99% (can be increased to up to 19.99% with 61 days' notice).
• · The offering was made under shelf registration statement File No. 333-286057, effective April 4, 2025.
• · The final prospectus supplement was filed with the SEC on July 1, 2026.

02-07-2026

Solid Power appointed Uwe Breitweg, VP Powertrain, Emission and Battery Strategy at BMW Group, to its board of directors effective July 1, 2026, pursuant to BMW Holding B.V.'s director nomination rights. He replaces Dr. Feurer, who is thanked for his service. The appointment strengthens the strategic partnership between Solid Power and BMW.

• · Uwe Breitweg has over 20 years of automotive leadership experience, including roles as VP Powertrain Systems Industrial Customers (2016-2021) and current VP Powertrain, Emission and Battery Strategy (since 2021) at BMW Group.
• · The appointment was made pursuant to BMW Holding B.V.'s director nomination rights.
• · Solid Power's business model involves selling its electrolyte to cell manufacturers and licensing cell designs and manufacturing processes.

02-07-2026

CareView Communications Inc. entered into the Fifteenth Amendment to its Credit Agreement with lender PDL Investment Holdings, LLC, extending the maturity date from June 30, 2026 to September 30, 2026. This is the latest in a long series of short-term extensions, indicating ongoing reliance on lender forbearance and no resolution of the company's debt obligations.

• · The Fifteenth Amendment to the Credit Agreement was entered into on June 30, 2026.
• · The amendment extends the Maturity Date to September 30, 2026.
• · The original Credit Agreement was dated June 26, 2015.
• · The company has entered into at least 14 prior amendments to the Credit Agreement and 30 amendments to the Modification Agreement.
• · The lender is PDL Investment Holdings, LLC, as assignee of PDL BioPharma, Inc.

02-07-2026

Idaho Copper Corporation announced the pricing of an $18 million underwritten public offering of common stock and warrants at $4.85 per share, with a 45-day over-allotment option for up to 556,800 additional shares. The offering is expected to close on July 6, 2026, and the shares will begin trading on the NYSE American on July 2, 2026. Proceeds will fund an updated Preliminary Economic Assessment, initial Prefeasibility Study work, and general corporate purposes.

• · The CuMo project is one of the largest undeveloped copper deposits in the western hemisphere and likely the largest undeveloped molybdenum deposit in the world.
• · The project contains significant amounts of silver, rhenium, and tungsten.
• · The registration statement on Form S-1 (File No. 333-290746) became effective on July 1, 2026.
• · ThinkEquity is acting as sole book-running manager for the offering.
• · The company's ticker symbols on NYSE American are COPR and COPR WS.

02-07-2026

StableCoinX Inc. filed an 8-K with audited financial statements for the period July 7, 2025 (inception) through December 31, 2025, reporting $0 in revenue and total assets, a net loss of $48,563, and negative stockholder's deficit of ($48,563). The company has a pending business combination with TLGY Acquisition Corporation and StablecoinX Assets Inc., with an extended outside date of July 21, 2026. However, the auditor's report includes a going concern qualification, noting substantial doubt about the company's ability to continue if it cannot complete the SPAC merger or raise additional funds within one year.

• · The company was incorporated on July 7, 2025, and its fiscal year ends December 31.
• · As of December 31, 2025, the company had 1 share of Class B common stock issued and outstanding and zero shares of Class A common stock.
• · Total operating expenses for the period were $48,563, all classified as general and administrative.
• · Accrued expenses of $18,900 and accrued expenses - related party of $29,663 comprised total liabilities.
• · The Business Combination Agreement has been amended twice to extend the outside date, currently set at July 21, 2026.
• · SC Assets' Decentralized Verifier Node (DVN) went live in November 2025; a subsequent DVN Services Agreement with Ethena Opco Ltd. on April 14, 2026 provides for a service fee of 1 basis point on bridged volume.
• · SC Assets' Validator Services went live in October 2025 and relies on a perpetual non-exclusive royalty-free software license with Schulz von Jacob Ltd., which is owned by the CTO of SC Assets.
• · The company's auditor, WithumSmith+Brown, PC, has served as auditor since 2025.
• · No cash was held at beginning or end of the period; net cash from operating, investing, and financing activities was all $0.
• · The company has no revenue and no operating history prior to 2025.

02-07-2026

Ares Acquisition Corporation III adopted amended and restated memorandum and articles of association on June 29, 2026, effective the same day, to facilitate its business combination strategy. The amendments include provisions for a 30-month extended period to complete a business combination, working capital withdrawals from the trust account, and conversion rights for Class B shares. The company has authorized share capital of US$999,999 divided into 9 billion Class A ordinary shares, 900 million Class B ordinary shares, and 99.99 million preference shares.

• · The company is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
• · The business combination must involve target businesses with an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding amounts disbursed for working capital and deferred underwriting discounts).
• · The company has 24 months from the closing of its IPO to complete a business combination, with an automatic extension of up to 30 months if a letter of intent is entered into.
• · Working capital withdrawals from the trust account are limited to $500,000 per year, with only $250,000 (plus rollover of unused interest) available in the six-month period beginning 24 months after the IPO if a letter of intent has been executed.
• · The company may redeem public shares if a business combination is not completed within the required timeframe.

02-07-2026

Elicio Therapeutics announced a $15 million registered direct offering of 4,380,313 shares, led by two new institutional investors with participation from an existing large shareholder. The net proceeds will primarily fund the planned Phase 1 clinical development of ELI-002 7P in metastatic PDAC and general corporate purposes. However, the company's Phase 2 AMPLIFY-7P trial showed immature overall survival data, and the Phase 1 study is subject to funding, highlighting ongoing clinical and financial risks.

• · The offering is being made under a shelf registration statement on Form S-3 (File No. 333-293861) declared effective on March 16, 2026.
• · Closing of the offering is expected on or about July 6, 2026.
• · ELI-002 7P targets seven of the most common KRAS mutations present in 25% of all solid tumors.
• · Phase 2 AMPLIFY-7P trial data for overall survival remained immature at the time of analysis.
• · Elicio plans to expand ELI-002 7P to other indications including mKRAS-positive lung cancer.
• · Pipeline includes ELI-007 (BRAF-driven cancers) and ELI-008 (p53 hotspot mutations).

02-07-2026

Vaxart, Inc. entered into a cooperation agreement with the Stockholder Group to resolve its proxy contest ahead of the 2026 Annual Meeting. The agreement includes appointing a mutually agreed independent director, forming a Stockholder Engagement Committee and a Clinical and Regulatory Affairs Committee, refreshing board committee chairs, and adopting director stock ownership and resignation policies. The Stockholder Group withdrew its director nominations. The settlement aims to unify focus on upcoming value-inflection milestones and enhance corporate governance, but no specific financial or operational targets were disclosed.

• · Vaxart is a clinical-stage biotechnology company developing oral recombinant vaccines using an adenovirus and TLR3 agonist platform.
• · The cooperation agreement includes formation of a Stockholder Engagement Committee and a Clinical and Regulatory Affairs Committee.
• · The agreement provides for board committee refreshment, including new chairs for the Nominating and Governance and Compensation Committees.
• · The cooperation agreement includes customary standstill, voting, and engagement provisions for the Stockholder Group.
• · The search for the additional independent director will be conducted within 90 days of the conclusion of the 2026 Annual Meeting.

02-07-2026

Arcturus Therapeutics announced a strategic collaboration with Thermo Fisher Scientific to support Phase 3 development and potential commercialization of ARCT-032, an investigational mRNA therapy for cystic fibrosis. Thermo Fisher will provide integrated manufacturing, clinical research, and commercial readiness services, with exclusive commercial manufacturing rights subject to regulatory approval. The collaboration leverages Thermo Fisher's Accelerator™ Drug Development solutions to help accelerate the program, though Phase 2 results are still pending and regulatory approval is uncertain.

• · Arcturus developed KOSTAIVE®, the first self-amplifying mRNA COVID vaccine approved globally.
• · Arcturus has an ongoing global collaboration with CSL Seqirus and U.S. BARDA for pandemic flu.
• · Arcturus has a joint venture in Japan, ARCALIS, focused on mRNA vaccine and therapeutic manufacturing.
• · Arcturus' pipeline includes RNA therapeutic candidates for cystic fibrosis and ornithine transcarbamylase (OTC) deficiency, plus partnered mRNA vaccine programs for COVID-19 and influenza.
• · Arcturus' technologies cover multiple nucleic acid medicines including mRNA, siRNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
• · Arcturus holds over 500 patents and patent applications globally.

02-07-2026

Kartoon Studios adopted a limited duration stockholder rights plan (poison pill) to protect shareholder interests, not in response to any specific takeover bid. The plan involves a dividend distribution of one right per outstanding common share, with a record date of July 13, 2026. The company continues to position itself for sustained growth through its global children's entertainment portfolio, including Stan Lee Universe and Mainframe Studios.

• · Kartoon Channel! is consistently rated as the #1 kids’ streaming app on the Apple App Store.
• · The company has a global distribution footprint in over 60 territories.
• · Kartoon Studios holds a controlling interest in Stan Lee Universe.
• · Mainframe Studios is one of North America’s largest animation producers.

02-07-2026

Cerence Inc. announced the resignation of board member Marcy Klevorn, effective July 1, 2026, for personal reasons and not due to any disagreement with the company. Ms. Klevorn served on the Compensation Committee and the Nominating and Governance Committee. The company expressed gratitude for her contributions.

• · Resignation effective July 1, 2026, notified on June 28, 2026.
• · Ms. Klevorn was a member of the Compensation Committee and the Nominating and Governance Committee.
• · No disagreement with the company's operations, policies, or accounting practices was cited.

02-07-2026

AlTi Global, Inc. amended the employment agreement of President and COO Kevin Moran, increasing his base salary to $600,000 and setting a 2026 target bonus of $1,600,000, while also formalizing an employment agreement with Interim CEO Nancy Curtin. The amendment reduces Moran's notice period from 180 to 30 days, but no financial performance data is provided in this filing.

• · The Amended Moran Agreement reduces the notice period under Exhibit A from 180 days to 30 days.
• · Nancy Curtin's appointment as Interim CEO was previously reported in a Form 8-K filed March 31, 2026.

02-07-2026

Dot Ai, Inc. (Nasdaq: DAIC) announced the retirement in full of its outstanding secured convertible promissory notes held by White Lion Capital, LLC, totaling approximately $867,000, releasing associated security interests and eliminating that debt. Additionally, a new investor has advanced $500,000 in new secured convertible financing as a first step toward a potential significant transaction. While these actions strengthen the balance sheet and simplify the capital structure, the company noted that the related letter of intent is non-binding and there is no assurance that a definitive transaction will be completed.

• · The retirement of the White Lion notes releases all security interests that secured those notes.
• · The new $500,000 convertible note is provided by a potential new investor previously contemplated in a non-binding LOI.
• · The LOI relates to a sale of a portion of the Company’s operating business, but is non-binding and subject to numerous conditions.
• · There is no assurance that definitive agreements will be executed or that the proposed transaction will be completed.
• · The company serves industries including aviation, construction, delivery, military, mining, retail, sea ports, medical logistics, warehousing, and manufacturing.

02-07-2026

Cingulate Inc. (NASDAQ: CING) announced its addition to the Russell 3000E® Index, a benchmark for institutional investors tracking approximately 4,000 of the largest investable US equities. CEO Shane Schaffer highlighted that the inclusion enhances visibility with institutional investors and supports long-term growth, while the company continues advancing its lead ADHD product candidate CTx-1301 and its Precision Timed Release™ platform. No negative or flat performance metrics were disclosed in this filing.

• · Russell 3000E Index measures performance of approximately 4,000 largest investable US equities and is fully reconstituted each June, with semi-annual reconstitution beginning December 2026.
• · US ADHD market estimated at approximately 100 million annual prescriptions.
• · Over 20 million U.S. patients diagnosed with ADHD: 12 million adults and over 8 million under age 17.
• · Only 53.6% of children and teens with ADHD reported actively treating with medication in 2022.
• · Adult ADHD prevalence is larger and growing faster than child and adolescent segments combined.
• · CTx-1301 is being evaluated under FDA's 505(b)(2) pathway for ADHD treatment.

02-07-2026

HUMBL, INC. (HMBL) reported revenue of $30 million for the quarter ended March 31, 2026, representing a 20% increase year-over-year. However, the company reported a net loss of $5 million, compared to a net loss of $4 million in the same period last year, and operating expenses increased by 15% to $28 million. The filing highlights strong growth in transaction volume, but also notes a decline in user growth rate and increasing operational costs.

• · Transaction volume grew by 40% YoY to $2.5 billion.
• · Cash and cash equivalents decreased to $8 million from $12 million in the prior year quarter.
• · Customer acquisition costs increased by 18% YoY.
• · HUMBL, INC. launched a new AI-driven recommendation engine during the quarter.

02-07-2026

Halozyme Therapeutics announced the departure of Cortney Caudill as Senior Vice President and Chief Operating Officer, effective June 30, 2026. The company also disclosed an update to its senior management structure but provided no further details on the new structure or any successor appointment.

• · The departure was announced on June 30, 2026, and the 8-K was filed on July 2, 2026.
• · No reason for the departure or details on the management structure update were provided in the filing.
• · No successor or interim COO was named.

02-07-2026

Centrus Energy signed a $900 million contract with the U.S. Department of Energy to deploy commercial-scale HALEU production capacity, with total contract value including options reaching $1.07 billion. The company completed production of an additional 900 kilograms of HALEU UF6 ahead of schedule, transitioning from a demonstration contract to commercialization. However, the first new capacity is not expected online until 2029, and the company faces risks including government funding uncertainties and geopolitical conflicts.

• · The demonstration contract was originally won in 2019 and modified/extended in 2022.
• · The new contract is fixed-price and includes options for up to $170 million in HALEU purchases.
• · Centrus expects the initial build-out to achieve nth-of-a-kind centrifuge manufacturing costs.
• · The expansion is underpinned by public and private funding including national security missions, third-party investments, prepayment, direct foreign investment, and commercial contracts.
• · Centrus has provided more than 1,850 reactor years of fuel since 1998, equivalent to more than 7 billion tons of coal.

02-07-2026

Motorcar Parts of America extended CEO Selwyn Joffe's employment agreement to July 1, 2029, and approved two salary increases: from $828,256 to $902,799 per annum effective June 26, 2026, and further to $984,050 per annum effective April 1, 2027. No negative or flat metrics are reported in this filing.

• · The Amendment was approved by the Human Resources and Compensation Committee and the Board of Directors.
• · All other terms of the Employment Agreement remain unchanged.
• · The term was extended by two years, from July 1, 2027 to July 1, 2029.

02-07-2026

Sky Quarry Inc., together with co-obligors Foreland Refining Corp. and 2020 Resources LLC, entered into a Conversion and Exchange Agreement with Libertas Funding LLC to convert approximately $3.985M in outstanding merchant cash advance obligations into a single 8% promissory note, extinguishing all prior MCA agreements and remedies. The restructuring reduces near-term cash flow pressure from daily/weekly ACH debits and provides a more traditional debt structure, but the company remains highly leveraged. CEO Marcus Laun is providing a personal guarantee on the new note.

• · The MCA Agreements originated from fundings on October 23, 2023, January 12, 2024, January 18, 2024, and February 23, 2024.
• · The new note carries an 8% interest rate and is not registered under the Securities Act of 1933.
• · Libertas is an accredited investor and is acquiring the note for investment purposes only.
• · The conversion is irrevocable—MCA Agreements cannot be reinstated even in the event of a default under the note.
• · Upon closing, all prior MCA remedies including 'Bad Acts' provisions, ACH debit authorizations, and acceleration rights are nullified.
• · Closing conditions include execution of the note, personal guarantee, and no existing event of default under the note.
• · The agreement is governed by Delaware law.

02-07-2026

Grayscale Sui Staking ETF (GSUI) announced the appointment of Kathryn Masci and Daniel Plourde as interim Co-Chief Financial Officers of the sponsor, Grayscale Investments Sponsors, LLC, effective July 2, 2026, following the departure of Edward McGee, who stepped down for personal reasons after 7 years of service. Ms. Masci also joins the Board of Managers and will serve as Principal Financial and Accounting Officer of the registrant. The departures and appointments are described as amicable with no disagreements.

• · Kathryn Masci has been with Grayscale since May 2020 and served as Senior Vice President of Finance since January 2026.
• · Daniel Plourde joined Grayscale as Vice President in September 2022 and became Senior Vice President of Finance in January 2026; he has served as Assistant Treasurer of Grayscale Funds Trust since 2025.
• · Ms. Masci is a Certified Public Accountant licensed in New York and holds B.S. and M.S. in Accounting from Binghamton University.
• · Mr. Plourde has over 20 years of financial services experience and holds an MBA in Accounting from University of Massachusetts Boston.
• · Edward McGee's departure is for personal reasons and not due to any disagreement with the Company.

02-07-2026

Tenon Medical, Inc. announced a $4.2 million public offering of 11,052,631 shares (or pre-funded warrants) at a combined price of $0.38 per share with common warrants. Proceeds will be used for debt repayment, commercial expansion, and R&D. The offering is led by WallachBeth Capital, with the securities already registered with the SEC.

• · The offering includes up to 13,263,159 common warrants exercisable at $0.38 per share.
• · Pre-funded warrants are exercisable at $0.001 per share and may be exercised at any time until fully exercised.
• · The company expects to use net proceeds for partial repayment of outstanding convertible notes, commercial expansion, training clinicians, hiring direct sales reps, expanding distribution network, clinical research for reimbursement, R&D for future launches, inventory/instrumentation increases, marketing, and working capital.
• · Tenon acquired substantially all assets of SiVantage, Inc. and SIMPL Medical, LLC in August 2025, including the SImmetry+® SI Joint Fusion System.
• · The offering was priced on June 30, 2026.

02-07-2026

Bumble Inc. filed an 8-K on July 2, 2026, regarding Item 5.02, which covers the departure or appointment of officers and compensatory arrangements. The filing does not disclose specific names, positions, or reasons for the change, nor does it provide any financial metrics or forward-looking guidance. Without explicit details on the leadership change, its nature (appointment vs. resignation), or any quantitative data, the filing is purely informational with no directional bias for investors.

02-07-2026

LIXTE BIOTECHNOLOGY HOLDINGS, INC. filed an 8-K on July 2, 2026, reporting the completion of a material definitive agreement (Item 1.01) and the completion of an acquisition or disposition of assets (Item 2.01). The filing also includes unregistered sales of equity securities (Item 3.02), director/officer changes (Item 5.02), amendments to articles of incorporation (Item 5.03), and Regulation FD disclosure (Item 7.01). However, the filing does not disclose the specific transaction value, parties involved, deal structure, or financial metrics, making it impossible to assess the strategic rationale, valuation, or shareholder impact. The absence of quantitative data limits the analysis to a neutral, informational signal.

• · Filing includes Items 1.01, 2.01, 3.02, 5.02, 5.03, 7.01, 8.01, and 9.01, indicating a complex transaction with multiple regulatory triggers.
• · No financial statements or exhibits were summarized in the provided data; Item 9.01 suggests they are attached but not extracted.
• · The filing size is 1 MB, suggesting substantial documentation, but no specific details were provided in the summary.

02-07-2026

Veru Inc. entered into a Sales Agreement with Oppenheimer & Co. Inc. and Canaccord Genuity LLC to sell up to $21.8 million of its common stock in at-the-market offerings. The company will pay a 3.0% commission on gross proceeds and is not obligated to sell any shares. No prior-period comparisons are available in this filing.

• · The Sales Agreement was entered into on July 2, 2026.
• · The offering is registered under the Company's Registration Statement on Form S-3 (File No. 333-294911), effective April 15, 2026.
• · Sales may be made by any method permitted by law deemed an 'at the market offering' under Rule 415(a)(4).
• · The Company will reimburse the Sales Agents for certain specified expenses.
• · The Company has provided customary indemnification and contribution rights to the Sales Agents.

02-07-2026

Abacus Global Management, Inc. entered into a First Amendment to its Credit Agreement on June 29, 2026, securing $75 million in incremental term loans, bringing total commitments to $225 million. The amendment maintains existing interest rate terms (SOFR + 5.25% with a potential stepdown to 5.00%) and extends maturity to December 2030. Separately, director Sean McNealy resigned effective June 30, 2026, in connection with his planned retirement, with no disagreement with the company.

• · The Incremental Term Loans may be prepaid at any time in amounts of $1.0 million or greater, subject to a 1.00% premium if prepaid within 12 months of funding.
• · Undrawn amounts under the DDTL facility bear a commitment fee until drawn or cancelled.
• · Sean McNealy will remain as an advisor during a transition period and will resign from all subsidiary director/officer roles by December 31, 2026.
• · The Amendment was filed as Exhibit 10.1 to the 8-K.

02-07-2026

Analog Devices, Inc. entered into a new Credit Agreement dated July 2, 2026, with Bank of America as Administrative Agent and a syndicate of lenders including Citibank, JPMorgan Chase, Morgan Stanley, Barclays, and BNP Paribas. The agreement provides for committed loan facilities with pricing tied to the company's debt rating, ranging from 0.480% to 0.925% for Term SOFR/Alternative Currency Loans and facility fees from 0.020% to 0.075%. The agreement includes customary representations, covenants, and events of default, and allows for designated borrowers among the company's subsidiaries.

• · The Credit Agreement is dated July 2, 2026, and includes the Company and certain subsidiaries as Designated Borrowers.
• · The agreement provides for committed loans and includes a Term-Out Option (Section 2.19).
• · Interest rates are based on Term SOFR, Base Rate, or Alternative Currency rates (SONIA for Sterling, EURIBOR for Euro).
• · The agreement includes a financial covenant (Section 7.07) and negative covenants regarding Liens, Fundamental Changes, and Use of Proceeds.
• · The agreement contains standard events of default and remedies (Article VIII).
• · The agreement includes provisions for extension of maturity date (Section 2.14) and replacement of lenders (Section 10.13).
• · The agreement is governed by the laws of the State of New York (Section 10.14).

02-07-2026

FTAI Infrastructure Inc. (FIP) subsidiary Jefferson 2020 Bond Borrower LLC entered into a $230 million bridge loan credit agreement with Jefferies Finance LLC as administrative agent and sole lead arranger. The loan carries escalating interest margins starting at 5.50% (Term Benchmark) and requires a $20 million debt service reserve. Proceeds will refinance existing debt, fund the reserve, and pay transaction fees.

• · The loan is structured as a bridge facility with escalating interest margins that increase every 90 days, starting at 5.50% (Term Benchmark) and reaching 7.50% after 360 days.
• · The agreement includes mandatory prepayment provisions based on Excess Cash Flow (ECF Sweep) with a 75% sweep when Leverage Ratio >= 6.00:1.00 and 50% when < 6.00:1.00.
• · The borrower is required to maintain a $20 million debt service reserve account.
• · The loan is secured by collateral as defined in the Security Documents (Article X).
• · The agreement contains typical representations, warranties, covenants, and events of default for a secured credit facility.

02-07-2026

Xerox Holdings Corporation approved the 2026-2028 Transformation Retention Award Plan, effective July 1, 2026, to retain critical talent during its multi-year turnaround. The plan provides cash-based retention awards vesting in eight equal quarterly installments over two years, but notably excludes the CEO and CFO from participation. Awards are forfeited upon voluntary or involuntary termination except in Change in Control scenarios where accelerated vesting may occur.

• · The plan is effective July 1, 2026 and runs through 2028.
• · Participants include executive officers (excluding CEO and CFO), senior leaders, and other critical employees.
• · Awards are cash-based, expressed as fixed dollar amount, percentage of base salary, or percentage of target annual bonus.
• · Vesting occurs in eight equal quarterly installments over two years, paid within 30 days after each vesting date.
• · Upon termination (voluntary or involuntary) all unvested installments are forfeited, except in Change in Control scenarios.
• · In a Change in Control, the Committee may accelerate vesting; if terminated without Cause or for Good Reason within 12 months post-Change in Control, all unvested installments immediately vest and are paid within 30 days.

02-07-2026

Cheniere Corpus Christi Holdings, LLC entered into a $1.5B revolving credit agreement dated June 26, 2026, with lenders including The Bank of Nova Scotia (agent) and Société Générale (security trustee), to provide working capital for its Corpus Christi LNG project. The facility amends and restates a prior working capital facility. No financial performance data was provided in this filing.

• · The agreement is governed by Delaware law and includes covenants on limitations on indebtedness, liens, and restricted payments.
• · The facility is classified as Working Capital Debt under the Finance Documents and amends/restates the existing working capital facility agreement.
• · The agreement includes provisions for letters of credit (with specific forms for Transcontinental Gas Pipeline Company and Gas Supply letters), swing line loans, and incremental commitments.
• · The facility is secured under the Second Amended and Restated Common Security and Account Agreement dated June 15, 2022 (as amended).

02-07-2026

Backblaze, Inc. filed an 8-K on July 2, 2026, reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 9.01 (Financial Statements and Exhibits). The filing indicates a material agreement was entered into, but no specific financial terms, counterparty, or strategic details are disclosed in the summary. The filing is timely and mandatory, but the lack of quantitative data limits assessment of financial impact or market reaction.

• · Filing date: July 2, 2026
• · AccNo: 0001628280-26-046865
• · Size: 173 KB
• · Items reported: 1.01 and 9.01
• · No specific agreement details, counterparty, or financial terms disclosed in the summary

02-07-2026

Castellum, Inc. filed an 8-K on July 2, 2026, reporting entry into a material definitive agreement (Item 1.01) and departure/appointment of officers with compensatory arrangements (Item 5.02). No financial details or transaction values were disclosed. The filing is multi-item but lacks quantitative data, making assessment of materiality and market impact uncertain.

• · Filed on July 2, 2026, with AccNo 0001877939-26-000057.
• · Size of filing: 181 KB.
• · No financial statements or exhibits were provided in the summary.

02-07-2026

ABVC BIOPHARMA, INC. filed an 8-K on July 2, 2026, reporting a change in its certifying accountant (Item 4.01) and providing related financial statements and exhibits (Item 9.01). The filing discloses the dismissal of its previous independent registered public accounting firm and the engagement of a new one. No financial impact, transaction details, or forward-looking guidance are provided in the filing.

• · The filing is a mandatory disclosure under SEC rules for a change in auditor.
• · No financial statements, revenue, earnings, or guidance are included in this filing.
• · No transaction value, share count, or percentage changes are disclosed.

02-07-2026

Pyxis Oncology announced a private placement financing with gross proceeds of approximately $50 million upfront, plus up to $64 million from warrant exercises, led by BVF Partners L.P. The financing is expected to extend the company's cash runway into Q2 2027 and support the advancement of its lead ADC candidate MICVO through key clinical milestones. However, the company has delayed its next clinical data update for the Phase 1 monotherapy study to Fall 2026 (previously expected earlier), and the Phase 1/2 combination data is now expected in Q4 2026, indicating a shift in timelines.

• · The private placement is expected to close on or about July 2, 2026.
• · Wells Fargo Securities acted as sole placement agent.
• · The company has elected to incorporate additional patient follow-up and planned analyses into its next clinical update, delaying the monotherapy data release to Fall 2026.
• · The Phase 1/2 combination data with pembrolizumab is expected in Q4 2026.
• · MICVO received Fast Track Designation from the FDA for R/M HNSCC after progression on platinum-based chemotherapy and anti-PD-(L)1 therapy.
• · The warrants have a cashless exercise feature.

02-07-2026

W. P. Carey Inc. completed a public offering of $350 million in 5.200% Senior Notes due 2036 on July 2, 2026. The net proceeds will be used to repay $350 million of its 4.250% Senior Notes due October 2026 and for general corporate purposes, including funding potential investments and repaying other indebtedness. The offering was made under an existing shelf registration statement and a final prospectus supplement dated June 29, 2026.

• · The Senior Notes mature on September 15, 2036.
• · Interest on the Senior Notes is payable semi-annually on March 15 and September 15, commencing March 15, 2027.
• · The Senior Notes are unsecured and unsubordinated obligations ranking equally with existing and future unsecured and unsubordinated debt.
• · The company may redeem the notes at any time at the make-whole redemption price; after June 15, 2036, redemption price is 100% of principal plus accrued interest.
• · The indenture includes covenants requiring a specified ratio of unencumbered assets to unsecured debt and limiting incurrence of secured and unsecured indebtedness, subject to significant exceptions.
• · The offering was made under an automatic shelf registration statement (File No. 333-286885) filed on May 1, 2025.

02-07-2026

Dr. Mung Chiang resigned from the Board of Directors of First Merchants Corporation effective July 1, 2026, due to a change in professional responsibilities requiring relocation outside the company's primary market area. His resignation was not due to any disagreement with the company. The Board size decreased from 13 to 12 members.

• · Resignation effective July 1, 2026.
• · Dr. Chiang's resignation is not related to any disagreement with the company's operations, policies, or practices.
• · The Board size decreased from 13 to 12 members.

02-07-2026

CapsoVision appointed David S. Shields, M.D., a board-certified gastroenterologist with over 40 years of experience, to its Board of Directors effective July 1, 2026, succeeding Dr. Joanne C. Imperial who will continue as an independent clinical consultant. The company highlighted upcoming milestones including the commercial launch of its AI-assisted reading feature for CapsoCam Plus® and the advancement of its second-generation CapsoCam Colon™ program, though it also faces ongoing risks related to regulatory clearance and pipeline development.

• · Dr. Shields has served as a clinical advisor and consultant to CapsoVision for nearly a decade since 2017.
• · He accumulated nearly two decades of experience utilizing capsule endoscopy in the diagnosis and management of small bowel disorders and gastrointestinal bleeding.
• · Dr. Shields received his M.D. from UCSF School of Medicine and completed residency at Stanford and University of Virginia.
• · The filing includes forward-looking statements regarding risks such as market conditions, available financing, regulatory clearance, and product adaptation for new indications.
• · The company continues to work on its CapsoCam® UGI clinical study for pancreatic cancer detection.

02-07-2026

Kodiak AI, Inc. filed an 8-K on July 2, 2026, reporting an officer change under Item 5.02, which covers the departure or appointment of directors and officers, as well as compensatory arrangements. The filing also includes Item 9.01 for financial statements and exhibits. No specific names, titles, reasons, or financial metrics are disclosed in the provided summary, limiting the ability to assess the nature or materiality of the change.

• · Filing size is 193 KB, indicating potential exhibits or detailed disclosures not summarized.
• · AccNo: 0001628280-26-046850 suggests a standard SEC filing sequence.
• · Sector is not specified, limiting industry context.

02-07-2026

Grayscale Solana Staking ETF (GSOL) announced the appointment of Kathryn Masci and Daniel Plourde as interim Co-Chief Financial Officers of the sponsor, Grayscale Investments Sponsors, LLC, effective July 2, 2026, succeeding Edward McGee who stepped down for personal reasons after 7 years of service. Ms. Masci also joins the Board of Managers and becomes Principal Financial and Accounting Officer of the registrant. The departures and appointments are amicable with no disagreements cited.

• · Kathryn Masci has been with Grayscale since May 2020 and served as Senior Vice President of Finance since January 2026.
• · Daniel Plourde joined Grayscale as Vice President in September 2022 and became Senior Vice President in January 2026; he also serves as Assistant Treasurer of the Grayscale Funds Trust since 2025.
• · Ms. Masci is a CPA licensed in New York and holds B.S. and M.S. in Accounting from Binghamton University.
• · Mr. Plourde holds an MBA in Accounting from University of Massachusetts Boston and has over 20 years of financial services experience.

02-07-2026

Alpha Modus Holdings, Inc. entered into a Securities Purchase Agreement with Streeterville Capital, LLC on June 29, 2026, for the issuance of common shares through pre-paid purchases. The agreement includes provisions for registration, listing, and an exchange cap under Nasdaq rules, with shareholder approval required to exceed the cap. No specific monetary amounts or share quantities are disclosed in the filing.

• · The agreement relies on an exemption from securities registration under the Securities Act of 1933.
• · Company must file a PRE14C with the SEC within 30 days of closing and a DEF14C to notify stockholders of the approval to exceed the Exchange Cap.
• · Company is obligated to cure any Material Outside Event within 10 Trading Days.
• · Company must publicly disclose all material non-public information delivered to Investor after filing the Current Report.

02-07-2026

Elroy Air, Inc. entered into a Securities Purchase Agreement on June 25, 2026, to issue convertible promissory notes and warrants to institutional investors in a private placement under Section 4(a)(2) of the Securities Act. The financing is part of a broader transaction that includes a Business Combination Agreement with SPAC Columbus Circle Capital Corp II (CMII). The filing does not disclose specific dollar amounts, conversion terms, or warrant details, limiting immediate quantitative assessment.

• · The Securities Purchase Agreement is dated June 25, 2026, and involves institutional investors as purchasers.
• · The securities are being offered under Section 4(a)(2) of the Securities Act, exempt from public registration.
• · The Company is concurrently entering into a separate securities purchase agreement (Other SPA) with other purchasers on substantially the same terms.
• · The Business Combination Agreement with SPAC Columbus Circle Capital Corp II is anticipated but not yet executed as of the filing date.
• · Purchasers must be qualified institutional buyers or institutional accredited investors under Rule 144A or Rule 501(a).
• · The securities are subject to transfer restrictions and will bear a restrictive legend.
• · The Purchaser releases the Placement Agent from any losses or claims related to the offering.
• · No specific dollar amounts, conversion prices, interest rates, or warrant exercise prices are disclosed in this exhibit.

02-07-2026

Haverty Furniture Companies Inc. and its subsidiary Havertys Credit Services Inc. entered into a Sixth Amendment to their Amended and Restated Credit Agreement with Truist Bank, effective June 29, 2026. The amendment increases the revolving loan commitments from $80 million to $100 million, providing additional liquidity. The filing confirms no defaults are continuing and all representations and warranties remain true.

• · The amendment was entered into on June 29, 2026, and filed on July 2, 2026.
• · The credit agreement was originally dated September 1, 2011.
• · No Default or Event of Default is continuing as of the effective date.
• · The amendment is governed by the internal laws of the State of Georgia.
• · The amendment reaffirms the security interests and liens granted to the Administrative Agent under the credit agreement.

02-07-2026

Ares Core Infrastructure Fund (the Equityholder and Servicer) and its SPV subsidiary ACI Liquid Aggregator SPV, LLC amended their existing revolving credit and security agreement with BNP Paribas (Administrative Agent and Lender) and U.S. Bank Trust Company (Collateral Agent) on June 26, 2026. The amendment updates terms via redlined changes to the agreement, schedules, and exhibits; the borrower and servicer represent no default is continuing and all representations remain true. No specific financial metrics or performance data were disclosed in the filing, limiting the ability to assess the fund's financial trajectory.

• · The underlying Revolving Credit and Security Agreement was originally dated September 23, 2025.
• · No monetary amounts or changes to facility size, interest rates, or fees were disclosed in the amendment.
• · The amendment was governed by New York law and required a legal opinion from Latham & Watkins LLP.
• · The borrower represented that no Default or Event of Default is continuing as of the amendment date.